During the corresponding time, Embecta Corp saw a revenue deteriorated by -7.93 % year on year, sequentially revenue grew by 22.5 %. While revenue at the Embecta Corp 's corporate clients
Embecta's Comment on Sales, Marketing and Customers
The company operates globally, primarily serving the diabetes market with products such as pen needles and insulin syringes. Its raw materials include cannula, plastic resin, adhesive, needle lubricants, rubber stoppers, and packaging materials, which are mostly sourced from single or limited suppliers to maintain quality and supply continuity. After separating from Becton, Dickinson and Company (BD) in 2022, the company entered into a cannula supply agreement with BD, which retained ownership of cannula production and related intellectual property. The company is also pursuing product development beyond diabetes into drug delivery and chronic care markets, utilizing its manufacturing and distribution expertise. Its intellectual property portfolio comprises approximately 655 patents and 45 pending patent applications worldwide, covering features related to safety, comfort, ease of use, and visual aspects of its pen needle and syringe products.
Empowering Type 2 Diabetes Management: FDA Clears embecta s Revolutionary Disposable Insulin Patch PumpIn a landmark achievement poised to transform the landscape of diabetes care, embecta has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative disposable insulin delivery system. This state-of-the-art patch pump, meticulously designed to address the unique demands of individuals managing Type 2 diabetes, features a robust 300-unit insulin reservoir, signifying a significant stride in diabetes management technology. Bridging the Gap in Type 2 Diabetes CareDiabetes mellitus, particularly Type 2, represents a chronic health challenge that calls for innovative solutions ...
The Advanced Technologies and Treatments for Diabetes (ATTD) international conference witnessed a catalyzing moment as embecta, a leading medical technology company, announced its sponsorship of a symposium and six abstracts focused on the crucial role of insulin pumps in managing type 2 diabetes. The event showcased groundbreaking research, strategies, and technological advancements that pave the way for a brighter future in type 2 diabetes management. In this article, we will delve into the highlights of this symposium and explore the implications for the millions of individuals affected by this chronic disease.Insulin Pumps as an Essential Tool in Type 2 Diabetes Management:Insulin pumps have been widely ...
Embecta’s Comment on Sales, Marketing and Customers
The company operates globally, primarily serving the diabetes market with products such as pen needles and insulin syringes. Its raw materials include cannula, plastic resin, adhesive, needle lubricants, rubber stoppers, and packaging materials, which are mostly sourced from single or limited suppliers to maintain quality and supply continuity. After separating from Becton, Dickinson and Company (BD) in 2022, the company entered into a cannula supply agreement with BD, which retained ownership of cannula production and related intellectual property. The company is also pursuing product development beyond diabetes into drug delivery and chronic care markets, utilizing its manufacturing and distribution expertise. Its intellectual property portfolio comprises approximately 655 patents and 45 pending patent applications worldwide, covering features related to safety, comfort, ease of use, and visual aspects of its pen needle and syringe products.
Sources:
Embecta Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Embecta Corp’s corporate clients.
For your research, we’ve provided 9 tables on Embecta Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
127.75 %